Jennison Associates
ONCE

Jennison Associates’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Jennison Associates’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-305,506
Closed -$27.2M – 711
2017
Q3 		$27.2M Buy
+305,506
New +$23.2M 0.03% 361

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates's ONCE Position: Q4 2017 in Review

Jennison Associates sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 305,506 shares — an estimated $27.2M sold.

Jennison Associates first reported a position in ONCE in Q3 2017 and held it in 1 quarter. The position peaked at $27.2M in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Jennison Associates reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Jennison Associates sold 305,506 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $27.2M.
  • Jennison Associates first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Jennison Associates's Spark Therapeutics, Inc. Common Stock position peaked at $27.2M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Jennison Associates's 13F filing for Q4 2017, filed 25 Jan 2018.